CoChat
Sign Up
Cited by 53Immune Cell Function and InteractionCancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Leukocyte immunoglobulin-like receptor subfamily B: therapeutic targets in cancer

Open access
Deng, Mi, Chen, Heyu, Liu, Xiaoye, Huang, Ryan, He, Yubo, Yoo, Byounggyu, Xie, Jingjing, John, Samuel +3 more·2021·Antibody Therapeutics
DOI 10.1093/abt/tbab002PMC PMC7944505
Open this paper in CoChat — free account

Abstract

Inhibitory leukocyte immunoglobulin-like receptors (LILRBs 1–5) transduce signals via intracellular immunoreceptor tyrosine-based inhibitory motifs that recruit phosphatases to negatively regulate immune activation. The activation of LILRB signaling in immune cells may contribute to immune evasion. In addition, the expression and signaling of LILRBs in cancer cells especially in certain hematologic malignant cells directly support cancer development. Certain LILRBs thus have dual roles in cancer biology—as immune checkpoint molecules and tumor-supporting factors. Here, we review the expression, ligands, signaling, and functions of LILRBs, as well as therapeutic development targeting them. LILRBs may represent attractive targets for cancer treatment, and antagonizing LILRB signaling may prove to be effective anti-cancer strategies.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/abt/tbab002

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 291

  1. [1]Wei, SC, Duffy, CR, Allison, JP. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov 2018; 8: 1069– 86. 30115704
  2. [2]Marasco, M, Berteotti, A, Weyershaeuser, J et al. Molecular mechanism of SHP2 activation by PD-1 stimulation. Sci Adv 2020; 6: eaay4458. 32064351 PMC6994217
  3. [3]Ravetch, JV, Lanier, LL. Immune inhibitory receptors. Science 2000; 290: 84– 9. 11021804
  4. [4]Dong, Z, Veillette, A. How do SAP family deficiencies compromise immunity? Trends Immunol 2010; 31: 295– 302. 20650688
  5. [5]Takai, T, Nakamura, A, Endo, S. Role of PIR-B in autoimmune glomerulonephritis. J Biomed Biotechnol 2011; 2011: 275302. 20976309 PMC2952822
  6. [6]Daeron, M, Jaeger, S, Du Pasquier, L et al. Immunoreceptor tyrosine-based inhibition motifs: a quest in the past and future. Immunol Rev 2008; 224: 11– 43. 18759918
  7. [7]Katz, HR. Inhibition of inflammatory responses by leukocyte Ig-like receptors. Adv Immunol 2006; 91: 251– 72. 16938543
  8. [8]Noy, R, Pollard, JW. Tumor-associated macrophages: from mechanisms to therapy. Immunity 2014; 41: 49– 61. 25035953 PMC4137410
  9. [9]Mantovani, A, Marchesi, F, Malesci, A et al. Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol 2017; 14: 399– 416. 28117416 PMC5480600
  10. [10]Fleming, V, Hu, X, Weber, R et al. Targeting myeloid-derived suppressor cells to bypass tumor-induced immunosuppression. Front Immunol 2018; 9: 398. 29552012 PMC5840207
  11. [11]DeVito, NC, Plebanek, MP, Theivanthiran, B et al. Role of tumor-mediated dendritic cell tolerization in immune evasion. Front Immunol 2019; 10: 2876. 31921140 PMC6914818
  12. [12]Zhao, Y, van Woudenbergh, E, Zhu, J et al. The orphan immune receptor LILRB3 modulates fc receptor–mediated functions of neutrophils. J Immunol 2020; 204: 954– 66. 31915259 PMC7617070
  13. [13]Schuijs, MJ, Png, S, Richard, AC et al. ILC2-driven innate immune checkpoint mechanism antagonizes NK cell antimetastatic function in the lung. Nat Immunol 2020; 21: 998– 1009. 32747815 PMC7116357
  14. [14]Sarvaria, A, Madrigal, JA, Saudemont, A. B cell regulation in cancer and anti-tumor immunity. Cell Mol Immunol 2017; 14: 662– 74. 28626234 PMC5549607
  15. [15]Staub, E, Rosenthal, A, Hinzmann, B. Systematic identification of immunoreceptor tyrosine-based inhibitory motifs in the human proteome. Cell Signal 2004; 16: 435– 56. 14709333
  16. [16]Borges, L, Hsu, ML, Fanger, N et al. A family of human lymphoid and myeloid Ig-like receptors, some of which bind to MHC class I molecules. J Immunol 1997; 159: 5192– 6. 9548455
  17. [17]Colonna, M, Navarro, F, Bellon, T et al. A common inhibitory receptor for major histocompatibility complex class I molecules on human lymphoid and myelomonocytic cells. J Exp Med 1997; 186: 1809– 18. 9382880 PMC2199153
  18. [18]Cella, M, Dohring, C, Samaridis, J et al. A novel inhibitory receptor (ILT3) expressed on monocytes, macrophages, and dendritic cells involved in antigen processing. J Exp Med 1997; 185: 1743– 51. 9151699 PMC2196312
  19. [19]Samaridis, J, Colonna, M. Cloning of novel immunoglobulin superfamily receptors expressed on human myeloid and lymphoid cells: structural evidence for new stimulatory and inhibitory pathways. Eur J Immunol 1997; 27: 660– 5. 9079806
  20. [20]Martin, AM, Kulski, JK, Witt, C et al. Leukocyte Ig-like receptor complex (LRC) in mice and men. Trends Immunol 2002; 23: 81– 8. 11929131
  21. [21]Carosella, ED, Rouas-Freiss, N, Roux, DT et al. HLA-G: an immune checkpoint molecule. Adv Immunol 2015; 127: 33– 144. 26073983
  22. [22]Wende, H, Colonna, M, Ziegler, A et al. Organization of the leukocyte receptor cluster (LRC) on human chromosome 19q13.4. Mamm Genome 1999; 10: 154– 60. 9922396
  23. [23]Bernard, D, Hansen, JD, Du Pasquier, L et al. Costimulatory receptors in jawed vertebrates: conserved CD28, odd CTLA4 and multiple BTLAs. Dev Comp Immunol 2007; 31: 255– 71. 16928399
  24. [24]Truong, AD, Hong, Y, Lee, J et al. Chicken novel leukocyte immunoglobulin-like receptor subfamilies B1 and B3 are transcriptional regulators of major histocompatibility complex class I genes and signaling pathways. Asian-Australas J Anim Sci 2019; 32: 614– 28. 30381742 PMC6502725
  25. [25]Truong, AD, Hong, Y, Tran, HTT et al. Characterization and functional analyses of novel chicken leukocyte immunoglobulin-like receptor subfamily B members 4 and 5. Poult Sci 2019; 98: 6989– 7002. 31376355 PMC8913971
  26. [26]Canavez, F, Young, NT, Guethlein, LA et al. Comparison of chimpanzee and human leukocyte Ig-like receptor genes reveals framework and rapidly evolving genes. J Immunol 2001; 167: 5786– 94. 11698452
  27. [27]Dennis, G Jr, Kubagawa, H, Cooper, MD. Paired Ig-like receptor homologs in birds and mammals share a common ancestor with mammalian Fc receptors. Proc Natl Acad Sci U S A 2000; 97: 13245– 50. 11078516 PMC27210
  28. [28]Kubagawa, H, Burrows, PD, Cooper, MD. A novel pair of immunoglobulin-like receptors expressed by B cells and myeloid cells. Proc Natl Acad Sci U S A 1997; 94: 5261– 6. 9144225 PMC24666
  29. [29]Katz, HR, Vivier, E, Castells, MC et al. Mouse mast cell gp49B1 contains two immunoreceptor tyrosine-based inhibition motifs and suppresses mast cell activation when coligated with the high-affinity fc receptor for IgE. Proc Natl Acad Sci U S A 1996; 93: 10809– 14. 8855262 PMC38237
  30. [30]Atwal, JK, Pinkston-Gosse, J, Syken, J et al. PirB is a functional receptor for myelin inhibitors of axonal regeneration. Science 2008; 322: 967– 70. 18988857
  31. [31]Kim, T, Vidal, GS, Djurisic, M et al. Human LilrB2 is a beta-amyloid receptor and its murine homolog PirB regulates synaptic plasticity in an Alzheimer’s model. Science 2013; 341: 1399– 404. 24052308 PMC3853120
  32. [32]Olde Nordkamp, MJ, van Eijk, M, Urbanus, RT et al. Leukocyte-associated Ig-like receptor-1 is a novel inhibitory receptor for surfactant protein D. J Leukoc Biol 2014; 96: 105– 11. 24585933
  33. [33]Meyaard, L, Adema, GJ, Chang, C et al. LAIR-1, a novel inhibitory receptor expressed on human mononuclear leukocytes. Immunity 1997; 7: 283– 90. 9285412
  34. [34]Poggi, A, Pella, N, Morelli, L et al. p40, a novel surface molecule involved in the regulation of the non-major histocompatibility complex-restricted cytolytic activity in humans. Eur J Immunol 1995; 25: 369– 76. 7875198
  35. [35]Lebbink, RJ, de Ruiter, T, Adelmeijer, J et al. Collagens are functional, high affinity ligands for the inhibitory immune receptor LAIR-1. J Exp Med 2006; 203: 1419– 25. 16754721 PMC2118306
  36. [36]Kang, X, Lu, Z, Cui, C et al. The ITIM-containing receptor LAIR1 is essential for acute myeloid leukaemia development. Nat Cell Biol 2015; 17: 665– 77. 25915125 PMC4417000
  37. [37]Zheng, J, Umikawa, M, Cui, C et al. Inhibitory receptors bind ANGPTLs and support blood stem cells and leukaemia development. Nature 2012; 485: 656– 60. 22660330 PMC3367397
  38. [38]Liu, X, Yu, X, Xie, J et al. ANGPTL2/LILRB2 signaling promotes the propagation of lung cancer cells. Oncotarget 2015; 6: 21004– 154. 26056041 PMC4673246
  39. [39]Wang, L, Geng, T, Guo, X et al. Co-expression of immunoglobulin-like transcript 4 and angiopoietin-like proteins in human non-small cell lung cancer. Mol Med Rep 2015; 11: 2789– 96. 25482926
  40. [40]Zhang, P, Yu, S, Li, H et al. ILT4 drives B7-H3 expression via PI3K/AKT/mTOR signalling and ILT4/B7-H3 co-expression correlates with poor prognosis in non-small cell lung cancer. FEBS Lett 2015; 589: 2248– 56. 26149216
  41. [41]Naji, A, Menier, C, Maki, G et al. Neoplastic B-cell growth is impaired by HLA-G/ILT2 interaction. Leukemia 2012; 26: 1889– 92. 22441169
  42. [42]Harly, C, Peyrat, MA, Netzer, S et al. Up-regulation of cytolytic functions of human Vdelta2-gamma T lymphocytes through engagement of ILT2 expressed by tumor target cells. Blood 2011; 117: 2864– 73. 21233315
  43. [43]Urosevic, M, Kamarashev, J, Burg, G et al. Primary cutaneous CD8+ and CD56+ T-cell lymphomas express HLA-G and killer-cell inhibitory ligand, ILT2. Blood 2004; 103: 1796– 8. 14592815
  44. [44]Zhang, Y, Lu, N, Xue, Y et al. Expression of immunoglobulin-like transcript (ILT)2 and ILT3 in human gastric cancer and its clinical significance. Mol Med Rep 2012; 5: 910– 6. 22246571 PMC3493079
  45. [45]Heidenreich, S, Zu Eulenburg, C, Hildebrandt, Y et al. Impact of the NK cell receptor LIR-1 (ILT-2/CD85j/LILRB1) on cytotoxicity against multiple myeloma. Clin Dev Immunol 2012; 2012: 652130. 22844324 PMC3400434
  46. [46]Colovai, AI, Tsao, L, Wang, S et al. Expression of inhibitory receptor ILT3 on neoplastic B cells is associated with lymphoid tissue involvement in chronic lymphocytic leukemia. Cytometry B Clin Cytom 2007; 72: 354– 62. 17266150
  47. [47]Liu, J, Wang, L, Gao, W et al. Inhibitory receptor immunoglobulin-like transcript 4 was highly expressed in primary ductal and lobular breast cancer and significantly correlated with IL-10. Diagn Pathol 2014; 9: 85. 24762057 PMC4045966
  48. [48]Sun, Y, Liu, J, Gao, P et al. Expression of Ig-like transcript 4 inhibitory receptor in human non-small cell lung cancer. Chest 2008; 134: 783– 8. 18625675
  49. [49]Pfistershammer, K, Lawitschka, A, Klauser, C et al. Allogeneic disparities in immunoglobulin-like transcript 5 induce potent antibody responses in hematopoietic stem cell transplant recipients. Blood 2009; 114: 2323– 32. 19617579
  50. [50]Suciu-Foca, N, Feirt, N, Zhang, QY et al. Soluble Ig-like transcript 3 inhibits tumor allograft rejection in humanized SCID mice and T cell responses in cancer patients. J Immunol 2007; 178: 7432– 41. 17513794
  51. [51]Cortesini, R. Pancreas cancer and the role of soluble immunoglobulin-like transcript 3 (ILT3). JOP 2007; 8: 697– 703. 17993722
  52. [52]Chen, Z, Shojaee, S, Buchner, M et al. Signalling thresholds and negative B-cell selection in acute lymphoblastic leukaemia. Nature 2015; 521: 357– 61. 25799995 PMC4441554
  53. [53]Ma, G, Pan, PY, Eisenstein, S et al. Paired immunoglobin-like receptor-B regulates the suppressive function and fate of myeloid-derived suppressor cells. Immunity 2011; 34: 385– 95. 21376641 PMC3064726
  54. [54]Kang, X, Kim, J, Deng, M et al. Inhibitory leukocyte immunoglobulin-like receptors: immune checkpoint proteins and tumor sustaining factors. Cell Cycle 2016; 15: 25– 40. 26636629 PMC4825776
  55. [55]Velten, FW, Duperrier, K, Bohlender, J et al. A gene signature of inhibitory MHC receptors identifies a BDCA3(+) subset of IL-10-induced dendritic cells with reduced allostimulatory capacity in vitro. Eur J Immunol 2004; 34: 2800– 11. 15368296
  56. [56]Beinhauer, BG, McBride, JM, Graf, P et al. Interleukin 10 regulates cell surface and soluble LIR-2 (CD85d) expression on dendritic cells resulting in T cell hyporesponsiveness in vitro. Eur J Immunol 2004; 34: 74– 80. 14971032
  57. [57]Vlad, G, Piazza, F, Colovai, A et al. Interleukin-10 induces the upregulation of the inhibitory receptor ILT4 in monocytes from HIV positive individuals. Hum Immunol 2003; 64: 483– 9. 12691698
  58. [58]Gregori, S, Casorati, M, Amuchastegui, S et al. Regulatory T cells induced by 1 alpha,25-dihydroxyvitamin D3 and mycophenolate mofetil treatment mediate transplantation tolerance. J Immunol 2001; 167: 1945– 53. 11489974
  59. [59]Griffin, MD, Lutz, W, Phan, VA et al. Dendritic cell modulation by 1alpha,25 dihydroxyvitamin D3 and its analogs: a vitamin D receptor-dependent pathway that promotes a persistent state of immaturity in vitro and in vivo. Proc Natl Acad Sci U S A 2001; 98: 6800– 5. 11371626 PMC34433
  60. [60]Inui, M, Sugahara-Tobinai, A, Fujii, H et al. Tolerogenic immunoreceptor ILT3/LILRB4 paradoxically marks pathogenic auto-antibody-producing plasmablasts and plasma cells in non-treated SLE. Int Immunol 2016; 28: 597– 604. 27742834
  61. [61]Waschbisch, A, Sanderson, N, Krumbholz, M et al. Interferon beta and vitamin D synergize to induce immunoregulatory receptors on peripheral blood monocytes of multiple sclerosis patients. PLoS One 2014; 9: e115488. 25551576 PMC4281069
  62. [62]Hunt, JS, Petroff, MG, Morales, P et al. HLA-G in reproduction: studies on the maternal-fetal interface. Hum Immunol 2000; 61: 1113– 7. 11137215
  63. [63]Tedla, N, Lee, CW, Borges, L et al. Differential expression of leukocyte immunoglobulin-like receptors on cord-blood-derived human mast cell progenitors and mature mast cells. J Leukoc Biol 2008; 83: 334– 43. 17998301
  64. [64]Mori, Y, Tsuji, S, Inui, M et al. Inhibitory immunoglobulin-like receptors LILRB and PIR-B negatively regulate osteoclast development. J Immunol 2008; 181: 4742– 51. 18802077
  65. [65]Gustafson, CE, Qi, Q, Hutter-Saunders, J et al. Immune checkpoint function of CD85j in CD8 T cell differentiation and aging. Front Immunol 2017; 8: 692. 28659925 PMC5469909
  66. [66]Cadena-Mota, S, Monsivais-Urenda, A, Salgado-Bustamante, M et al. Effect of cytomegalovirus infection and leukocyte immunoglobulin like receptor B1 polymorphisms on receptor expression in peripheral blood mononuclear cells. Microbiol Immunol 2018; 62: 755– 62. 30461037
  67. [67]Lee, S, Affandi, JS, Irish, AB et al. Cytomegalovirus infection alters phenotypes of different gammadelta T-cell subsets in renal transplant recipients with long-term stable graft function. J Med Virol 2017; 89: 1442– 52. 28198539
  68. [68]Makwana, N, Foley, B, Fernandez, S et al. CMV drives the expansion of highly functional memory T cells expressing NK-cell receptors in renal transplant recipients. Eur J Immunol 2017; 47: 1324– 34. 28586095
  69. [69]Rothe, K, Quandt, D, Schubert, K et al. Latent cytomegalovirus infection in rheumatoid arthritis and increased frequencies of cytolytic LIR-1+CD8+ T cells. Arthritis Rheum 2016; 68: 337– 46. PMC5066744 26314621
  70. [70]Mamessier, E, Sylvain, A, Thibult, ML et al. Human breast cancer cells enhance self-tolerance by promoting evasion from NK cell antitumor immunity. J Clin Invest 2011; 121: 3609– 22. 21841316 PMC3171102
  71. [71]Chen, H, Chen, Y, Deng, M et al. Antagonistic anti-LILRB1 monoclonal antibody regulates antitumor functions of natural killer cells. J Immunother Cancer 2020; 8: e000515. 32771992 PMC7418854
  72. [72]Pasero, C, Gravis, G, Guerin, M et al. Inherent and tumor-driven immune tolerance in the prostate microenvironment impairs natural killer cell antitumor activity. Cancer Res 2016; 76: 2153– 65. 27197252
  73. [73]Roberti, MP, Juliá, EP, Rocca, YS et al. Overexpression of CD85j in TNBC patients inhibits cetuximab-mediated NK-cell ADCC but can be restored with CD85j functional blockade. Eur J Immunol 2015; 45: 1560– 9. 25726929
  74. [74]Villa-Alvarez, M, Sordo-Bahamonde, C, Lorenzo-Herrero, S et al. Ig-like transcript 2 (ILT2) blockade and lenalidomide restore NK cell function in chronic lymphocytic Leukemia. Front Immunol 2018; 9: 2917. 30619281 PMC6297751
  75. [75]Lamar, DL, Weyand, CM, Goronzy, JJ. Promoter choice and translational repression determine cell type-specific cell surface density of the inhibitory receptor CD85j expressed on different hematopoietic lineages. Blood 2010; 115: 3278– 86. 20194892 PMC2858479
  76. [76]Davidson, CL, Li, NL, Burshtyn, DN. LILRB1 polymorphism and surface phenotypes of natural killer cells. Hum Immunol 2010; 71: 942– 9. 20600445
  77. [77]Yu, K, Davidson, CE, Burshtyn, DN. LILRB1 intron 1 has a polymorphic regulatory region that enhances transcription in NK cells and recruits YY1. J Immunol 2020; 204: 3030– 41. 32321755
  78. [78]Morandi, F, Ferretti, E, Castriconi, R et al. Soluble HLA-G dampens CD94/NKG2A expression and function and differentially modulates chemotaxis and cytokine and chemokine secretion in CD56bright and CD56dim NK cells. Blood 2011; 118: 5840– 50. 21989990
  79. [79]Bjorkstrom, NK, Riese, P, Heuts, F et al. Expression patterns of NKG2A, KIR, and CD57 define a process of CD56dim NK-cell differentiation uncoupled from NK-cell education. Blood 2010; 116: 3853– 64. 20696944
  80. [80]Beziat, V, Descours, B, Parizot, C et al. NK cell terminal differentiation: correlated stepwise decrease of NKG2A and acquisition of KIRs. PLoS One 2010; 5: e11966. 20700504 PMC2917352
  81. [81]Vendrame, E, Seiler, C, Ranganath, T et al. TIGIT is upregulated by HIV-1 infection and marks a highly functional adaptive and mature subset of natural killer cells. AIDS 2020; 34: 801– 13. 32028328 PMC7148170
  82. [82]Freud, AG, Mundy-Bosse, BL, Yu, J et al. The broad spectrum of human natural killer cell diversity. Immunity 2017; 47: 820– 33. 29166586 PMC5728700
  83. [83]Muntasell, A, Pupuleku, A, Cisneros, E et al. Relationship of NKG2C copy number with the distribution of distinct cytomegalovirus-induced adaptive NK cell subsets. J Immunol 2016; 196: 3818– 27. 26994220
  84. [84]Kim, A, Han, CJ, Driver, I et al. LILRB1 blockade enhances bispecific T cell engager antibody-induced tumor cell killing by effector CD8(+) T cells. J Immunol 2019; 203: 1076– 87. 31253728 PMC6680066
  85. [85]Larbi, A, Fulop, T. From "truly naive" to "exhausted senescent" T cells: when markers predict functionality. Cytometry A 2014; 85: 25– 35. 24124072
  86. [86]LeMaoult, J, Zafaranloo, K, Le Danff, C et al. HLA-G up-regulates ILT2, ILT3, ILT4, and KIR2DL4 in antigen presenting cells, NK cells, and T cells. FASEB J 2005; 19: 662– 4. 15670976
  87. [87]Nunez, SY, Ziblat, A, Secchiari, F et al. Human M2 macrophages limit NK cell effector functions through secretion of TGF-beta and engagement of CD85j. J Immunol 2018; 200: 1008– 15. 29282306
  88. [88]Chapman, TL, Heikeman, AP, Bjorkman, PJ. The inhibitory receptor LIR-1 uses a common binding interaction to recognize class I MHC molecules and the viral homolog UL18. Immunity 1999; 11: 603– 13. 10591185
  89. [89]Willcox, BE, Thomas, LM, Bjorkman, PJ. Crystal structure of HLA-A2 bound to LIR-1, a host and viral major histocompatibility complex receptor. Nat Immunol 2003; 4: 913– 9. 12897781
  90. [90]Shiroishi, M, Tsumoto, K, Amano, K et al. Human inhibitory receptors Ig-like transcript 2 (ILT2) and ILT4 compete with CD8 for MHC class I binding and bind preferentially to HLA-G. Proc Natl Acad Sci U S A 2003; 100: 8856– 61. 12853576 PMC166403
  91. [91]Lepin, EJ, Bastin, JM, Allan, DS et al. Functional characterization of HLA-F and binding of HLA-F tetramers to ILT2 and ILT4 receptors. Eur J Immunol 2000; 30: 3552– 61. 11169396
  92. [92]Allan, DS, Lepin, EJ, Braud, VM et al. Tetrameric complexes of HLA-E, HLA-F, and HLA-G. J Immunol Methods 2002; 268: 43– 50. 12213342
  93. [93]Arnold, V, Cummings, JS, Moreno-Nieves, UY et al. S100A9 protein is a novel ligand for the CD85j receptor and its interaction is implicated in the control of HIV-1 replication by NK cells. Retrovirology 2013; 10: 122. 24156302 PMC3826667
  94. [94]Saito, F, Hirayasu, K, Satoh, T et al. Immune evasion of Plasmodium falciparum by RIFIN via inhibitory receptors. Nature 2017; 552: 101– 5. 29186116 PMC5748893
  95. [95]Harrison, TE, Morch, AM, Felce, JH et al. Structural basis for RIFIN-mediated activation of LILRB1 in malaria. Nature 2020; 587: 309– 12. 32650338 PMC7116854
  96. [96]Dulberger, CL, McMurtrey, CP, Holzemer, A et al. Human leukocyte antigen F presents peptides and regulates immunity through interactions with NK cell receptors. Immunity 2017; 46: 1018– 29.e7. 28636952 PMC5523829
  97. [97]Chan, KR, Ong, EZ, Tan, HC et al. Leukocyte immunoglobulin-like receptor B1 is critical for antibody-dependent dengue. Proc Natl Acad Sci U S A 2014; 111: 2722– 7. 24550301 PMC3932915
  98. [98]Ong, EZ, Zhang, SL, Tan, HC et al. Dengue virus compartmentalization during antibody-enhanced infection. Sci Rep 2017; 7: 40923. 28084461 PMC5234037
  99. [99]Upasani, V, Vo, HTM, Ung, S et al. Impaired antibody-independent immune response of B cells in patients with acute dengue infection. Front Immunol 2019; 10: 2500. 31736948 PMC6834554
  100. [100]Shiroishi, M, Kuroki, K, Tsumoto, K et al. Entropically driven MHC class I recognition by human inhibitory receptor leukocyte Ig-like receptor B1 (LILRB1/ILT2/CD85j). J Mol Biol 2006; 355: 237– 48. 16305801
  101. [101]Chapman, TL, Heikema, AP, West, AP Jr et al. Crystal structure and ligand binding properties of the D1D2 region of the inhibitory receptor LIR-1 (ILT2). Immunity 2000; 13: 727– 36. 11114384
  102. [102]Allen, RL, Raine, T, Haude, A et al. J Immunol 2001; 167: 5543– 7. 11698424
  103. [103]Kuroki, K, Matsubara, H, Kanda, R et al. Structural and functional basis for LILRB immune checkpoint receptor recognition of HLA-G isoforms. J Immunol 2019; 203: 3386– 94. 31694909
  104. [104]Wang, Q, Song, H, Cheng, H et al. Structures of the four Ig-like domain LILRB2 and the four-domain LILRB1 and HLA-G1 complex. Cell Mol Immunol 2020; 17: 966– 75. 31273318 PMC7609294
  105. [105]Vitale, M, Castriconi, R, Parolini, S et al. The leukocyte Ig-like receptor (LIR)-1 for the cytomegalovirus UL18 protein displays a broad specificity for different HLA class I alleles: analysis of LIR-1 + NK cell clones. Int Immunol 1999; 11: 29– 35. 10050671
  106. [106]Navarro, F, Llano, M, Bellon, T et al. The ILT2(LIR1) and CD94/NKG2A NK cell receptors respectively recognize HLA-G1 and HLA-E molecules co-expressed on target cells. Eur J Immunol 1999; 29: 277– 83. 9933109
  107. [107]Morel, E, Bellón, T. HLA class I molecules regulate IFN-γ production induced in NK cells by target cells, viral products, or immature dendritic cells through the inhibitory receptor ILT2/CD85j. J Immunol 2008; 181: 2368– 81. 18684926
  108. [108]Favier, B, Lemaoult, J, Lesport, E et al. ILT2/HLA-G interaction impairs NK-cell functions through the inhibition of the late but not the early events of the NK-cell activating synapse. FASEB J 2010; 24: 689– 99. 19841038
  109. [109]Ponte, M, Cantoni, C, Biassoni, R et al. Inhibitory receptors sensing HLA-G1 molecules in pregnancy: decidua-associated natural killer cells express LIR-1 and CD94/NKG2A and acquire p49, an HLA-G1-specific receptor. Proc Natl Acad Sci U S A 1999; 96: 5674– 9. 10318943 PMC21919
  110. [110]Petroff, MG, Sedlmayr, P, Azzola, D et al. Decidual macrophages are potentially susceptible to inhibition by class Ia and class Ib HLA molecules. J Reprod Immunol 2002; 56: 3– 17. 12106880
  111. [111]Kirwan, SE, Burshtyn, DN. Killer cell Ig-like receptor-dependent signaling by Ig-like transcript 2 (ILT2/CD85j/LILRB1/LIR-1). J Immunol 2005; 175: 5006– 15. 16210603
  112. [112]Fanger, NA, Cosman, D, Peterson, L et al. The MHC class I binding proteins LIR-1 and LIR-2 inhibit Fc receptor-mediated signaling in monocytes. Eur J Immunol 1998; 28: 3423– 34. 9842885
  113. [113]Lombardelli, L, Aguerre-Girr, M, Logiodice, F et al. HLA-G5 induces IL-4 secretion critical for successful pregnancy through differential expression of ILT2 receptor on decidual CD4+ T cells and macrophages. J Immunol 2013; 191: 3651– 62. 23997222
  114. [114]Lefebvre, S, Antoine, M, Uzan, S et al. Specific activation of the non-classical class I histocompatibility HLA-G antigen and expression of the ILT2 inhibitory receptor in human breast cancer. J Pathol 2002; 196: 266– 74. 11857488
  115. [115]Tenca, C, Merlo, A, Merck, E et al. CD85j (leukocyte Ig-like receptor-1/Ig-like transcript 2) inhibits human osteoclast-associated receptor-mediated activation of human dendritic cells. J Immunol 2005; 174: 6757– 63. 15905516
  116. [116]Apps, R, Gardner, L, Sharkey, AM et al. A homodimeric complex of HLA-G on normal trophoblast cells modulates antigen-presenting cells via LILRB1. Eur J Immunol 2007; 37: 1924– 37. 17549736 PMC2699429
  117. [117]Young, NT, Waller, EC, Patel, R et al. The inhibitory receptor LILRB1 modulates the differentiation and regulatory potential of human dendritic cells. Blood 2008; 111: 3090– 6. 18094328
  118. [118]Fedoric, B, Krishnan, R. Rapamycin downregulates the inhibitory receptors ILT2, ILT3, ILT4 on human dendritic cells and yet induces T cell hyporesponsiveness independent of FoxP3 induction. Immunol Lett 2008; 120: 49– 56. 18652845
  119. [119]Monsivais-Urenda, A, Gomez-Martin, D, Santana-de-Anda, K et al. Defective expression and function of the ILT2/CD85j regulatory receptor in dendritic cells from patients with systemic lupus erythematosus. Hum Immunol 2013; 74: 1088– 96. 23756160
  120. [120]Banham, AH, Colonna, M, Cella, M et al. Identification of the CD85 antigen as ILT2, an inhibitory MHC class I receptor of the immunoglobulin superfamily. J Leukoc Biol 1999; 65: 841– 5. 10380908
  121. [121]Young, NT, Uhrberg, M, Phillips, JH et al. Differential expression of leukocyte receptor complex-encoded Ig-like receptors correlates with the transition from effector to memory CTL. J Immunol 2001; 166: 3933– 41. 11238638
  122. [122]Saverino, D, Fabbi, M, Ghiotto, F et al. The CD85/LIR-1/ILT2 inhibitory receptor is expressed by all human T lymphocytes and down-regulates their functions. J Immunol 2000; 165: 3742– 55. 11034379
  123. [123]Ince, MN, Harnisch, B, Xu, Z et al. Increased expression of the natural killer cell inhibitory receptor CD85j/ILT2 on antigen-specific effector CD8 T cells and its impact on CD8 T-cell function. Immunology 2004; 112: 531– 42. 15270723 PMC1782522
  124. [124]Saverino, D, Merlo, A, Bruno, S et al. Dual effect of CD85/leukocyte Ig-like receptor-1/Ig-like transcript 2 and CD152 (CTLA-4) on cytokine production by antigen-stimulated human T cells. J Immunol 2002; 168: 207– 15. 11751964
  125. [125]Merlo, A, Saverino, D, Tenca, C et al. CD85/LIR-1/ILT2 and CD152 (cytotoxic T lymphocyte antigen 4) inhibitory molecules down-regulate the Cytolytic activity of human CD4+ T-cell clones specific for Mycobacterium tuberculosis. Infect Immun 2001; 69: 6022– 9. 11553539 PMC98730
  126. [126]Dietrich, J, Cella, M, Colonna, M. Ig-like transcript 2 (ILT2)/leukocyte Ig-like receptor 1 (LIR1) inhibits TCR signaling and actin cytoskeleton reorganization. J Immunol 2001; 166: 2514– 21. 11160312
  127. [127]Zhang, W, Liang, S, Wu, J et al. Human inhibitory receptor ILT2 amplifies CD11b+ Gr1+ myeloid-derived suppressor cells that promote long-term survival of allografts. Transplantation 2008; 86: 1125. 18946352 PMC2668611
  128. [128]Liang, S, Zhang, W, Horuzsko, A. Human ILT2 receptor associates with murine MHC class I molecules in vivo and impairs T cell function. Eur J Immunol 2006; 36: 2457– 71. 16897816
  129. [129]Lesport, E, Baudhuin, J, Sousa, S et al. Inhibition of human gamma delta [corrected] T-cell antitumoral activity through HLA-G: implications for immunotherapy of cancer. Cell Mol Life Sci 2011; 68: 3385– 99. 21337044 PMC11114898
  130. [130]Merlo, A, Tenca, C, Fais, F et al. Inhibitory receptors CD85j, LAIR-1, and CD152 down-regulate immunoglobulin and cytokine production by human B lymphocytes. Clin Diagn Lab Immunol 2005; 12: 705– 12. 15939744 PMC1151979
  131. [131]Naji, A, Menier, C, Morandi, F et al. Binding of HLA-G to ITIM-bearing Ig-like transcript 2 receptor suppresses B cell responses. J Immunol 2014; 192: 1536– 46. 24453251
  132. [132]Sayos, J, Martinez-Barriocanal, A, Kitzig, F et al. Recruitment of C-terminal Src kinase by the leukocyte inhibitory receptor CD85j. Biochem Biophys Res Commun 2004; 324: 640– 7. 15474475
  133. [133]Scott-Algara, D, Arnold, V, Didier, C et al. The CD85j+ NK cell subset potently controls HIV-1 replication in autologous dendritic cells. PLoS One 2008; 3: e1975. 18398485 PMC2276866
  134. [134]Huang, J, Burke, PS, Cung, TD et al. Leukocyte immunoglobulin-like receptors maintain unique antigen-presenting properties of circulating myeloid dendritic cells in HIV-1-infected elite controllers. J Virol 2010; 84: 9463– 71. 20631139 PMC2937602
  135. [135]Saverino, D, Ghiotto, F, Merlo, A et al. Specific recognition of the viral protein UL18 by CD85j/LIR-1/ILT2 on CD8+ T cells mediates the non-MHC-restricted lysis of human cytomegalovirus-infected cells. J Immunol 2004; 172: 5629– 37. 15100307
  136. [136]Wagner, CS, Riise, GC, Bergstrom, T et al. Increased expression of leukocyte Ig-like receptor-1 and activating role of UL18 in the response to cytomegalovirus infection. J Immunol 2007; 178: 3536– 43. 17339449
  137. [137]Reyburn, HT, Mandelboim, O, Vales-Gomez, M et al. The class I MHC homologue of human cytomegalovirus inhibits attack by natural killer cells. Nature 1997; 386: 514– 7. 9087413
  138. [138]Lozano, E, Diaz, T, Mena, MP et al. Loss of the immune checkpoint CD85j/LILRB1 on malignant plasma cells contributes to immune escape in multiple myeloma. J Immunol 2018; 200: 2581– 91. 29531171
  139. [139]Li, C, Houser, BL, Nicotra, ML et al. HLA-G homodimer-induced cytokine secretion through HLA-G receptors on human decidual macrophages and natural killer cells. Proc Natl Acad Sci U S A 2009; 106: 5767– 72. 19304799 PMC2667005
  140. [140]Desgrandchamps, F, LeMaoult, J, Goujon, A et al. Prediction of non-muscle-invasive bladder cancer recurrence by measurement of checkpoint HLAG's receptor ILT2 on peripheral CD8(+) T cells. Oncotarget 2018; 9: 33160– 9. 30237859 PMC6145700
  141. [141]Barkal, AA, Weiskopf, K, Kao, KS et al. Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy. Nat Immunol 2018; 19: 76– 84. 29180808 PMC5832354
  142. [142]Godal, R, Bachanova, V, Gleason, M et al. Natural killer cell killing of acute myelogenous leukemia and acute lymphoblastic leukemia blasts by killer cell immunoglobulin-like receptor-negative natural killer cells after NKG2A and LIR-1 blockade. Biol Blood Marrow Transplant 2010; 16: 612– 21. 20139023 PMC2854246
  143. [143]Churchill, HRO, Fuda, FS, Xu, J et al. Leukocyte immunoglobulin-like receptor B1 and B4 (LILRB1 and LILRB4): highly sensitive and specific markers of acute myeloid leukemia with monocytic differentiation. Cytometry B Clin Cytom 2020. doi: 10.1002/cyto.b.21952 32918786 · DOI
  144. [144]Favier, B. Regulation of neutrophil functions through inhibitory receptors: an emerging paradigm in health and disease. Immunol Rev 2016; 273: 140– 55. 27558333
  145. [145]Lewis Marffy, AL, McCarthy, AJ. Leukocyte immunoglobulin-like receptors (LILRs) on human neutrophils: modulators of infection and immunity. Front Immunol 2020; 11: 857. 32477348 PMC7237751
  146. [146]Colonna, M, Samaridis, J, Cella, M et al. Human myelomonocytic cells express an inhibitory receptor for classical and nonclassical MHC class I molecules. J Immunol 1998; 160: 3096– 100. 9531263
  147. [147]Fan, X, Shi, P, Dai, J et al. Paired immunoglobulin-like receptor B regulates platelet activation. Blood 2014; 124: 2421– 30. 25075127 PMC4192752
  148. [148]Lu, N, Li, Y, Zhang, Z et al. Human Semaphorin-4A drives Th2 responses by binding to receptor ILT-4. Nat Commun 2018; 9: 742. 29467366 PMC5821868
  149. [149]Manavalan, JS, Kim-Schulze, S, Scotto, L et al. Alloantigen specific CD8+CD28- FOXP3+ T suppressor cells induce ILT3+ ILT4+ tolerogenic endothelial cells, inhibiting alloreactivity. Int Immunol 2004; 16: 1055– 68. 15226269
  150. [150]Cosman, D, Fanger, N, Borges, L et al. A novel immunoglobulin superfamily receptor for cellular and viral MHC class I molecules. Immunity 1997; 7: 273– 82. 9285411
  151. [151]Wagtmann, N, Rojo, S, Eichler, E et al. A new human gene complex encoding the killer cell inhibitory receptors and related monocyte/macrophage receptors. Curr Biol 1997; 7: 615– 8. 9259559
  152. [152]Li, D, Wang, L, Yu, L et al. Ig-like transcript 4 inhibits lipid antigen presentation through direct CD1d interaction. J Immunol 2009; 182: 1033– 40. 19124746 PMC2646168
  153. [153]Li, D, Hong, A, Lu, Q et al. A novel role of CD1c in regulating CD1d-mediated NKT cell recognition by competitive binding to Ig-like transcript 4. Int Immunol 2012; 24: 729– 37. 22888216
  154. [154]Hofer, J, Forster, F, Isenman, DE et al. Ig-like transcript 4 as a cellular receptor for soluble complement fragment C4d. FASEB J 2016; 30: 1492– 503. 26678451
  155. [155]Deng, M, Lu, Z, Zheng, J et al. A motif in LILRB2 critical for Angptl2 binding and activation. Blood 2014; 124: 924– 35. 24899623 PMC4126332
  156. [157]Smith, LM, Kostylev, MA, Lee, S et al. Systematic and standardized comparison of reported amyloid-β receptors for sufficiency, affinity, and Alzheimer's disease relevance. J Biol Chem 2019; 294: 6042– 53. 30787106 PMC6463724
  157. [158]Masuda, A, Nakamura, A, Maeda, T et al. Cis binding between inhibitory receptors and MHC class I can regulate mast cell activation. J Exp Med 2007; 204: 907– 20. 17420263 PMC2118540
  158. [159]Kostlin, N, Ostermeir, AL, Spring, B et al. HLA-G promotes myeloid-derived suppressor cell accumulation and suppressive activity during human pregnancy through engagement of the receptor ILT4. Eur J Immunol 2017; 47: 374– 84. 27859042
  159. [160]Qiu, J, Terasaki, PI, Miller, J et al. Soluble HLA-G expression and renal graft acceptance. Am J Transplant 2006; 6: 2152– 6. 16780545
  160. [161]Manavalan, JS, Rossi, PC, Vlad, G et al. High expression of ILT3 and ILT4 is a general feature of tolerogenic dendritic cells. Transpl Immunol 2003; 11: 245– 58. 12967778
  161. [162]Bashirova, AA, Martin-Gayo, E, Jones, DC et al. LILRB2 interaction with HLA class I correlates with control of HIV-1 infection. PLoS Genet 2014; 10: e1004196. 24603468 PMC3945438
  162. [163]Bylinska, A, Wilczynska, K, Malejczyk, J et al. The impact of HLA-G, LILRB1 and LILRB2 gene polymorphisms on susceptibility to and severity of endometriosis. Mol Gen Genomics 2018; 293: 601– 13. PMC5948266 29234882
  163. [164]Brown, DP, Jones, DC, Anderson, KJ et al. The inhibitory receptor LILRB4 (ILT3) modulates antigen presenting cell phenotype and, along with LILRB2 (ILT4), is upregulated in response to salmonella infection. BMC Immunol 2009; 10: 56. 19860908 PMC2773765
  164. [165]Baudhuin, J, Migraine, J, Faivre, V et al. Exocytosis acts as a modulator of the ILT4-mediated inhibition of neutrophil functions. Proc Natl Acad Sci U S A 2013; 110: 17957– 62. 24133137 PMC3816409
  165. [166]Cai, Z, Wang, L, Han, Y et al. Immunoglobulinlike transcript 4 and human leukocyte antigen-G interaction promotes the progression of human colorectal cancer. Int J Oncol 2019; 54: 1943– 54. 30942436 PMC6521940
  166. [167]Zhang, Y, Zhao, J, Qiu, L et al. Co-expression of ILT4/HLA-G in human non-small cell lung cancer correlates with poor prognosis and ILT4-HLA-G interaction activates ERK signaling. Tumour Biol 2016; 37: 11187– 98. 26939901
  167. [168]Chen, HM, van der Touw, W, Wang, YS et al. Blocking immunoinhibitory receptor LILRB2 reprograms tumor-associated myeloid cells and promotes antitumor immunity. J Clin Invest 2018; 128: 5647– 62. 30352428 PMC6264729
  168. [169]Gregori, S, Tomasoni, D, Pacciani, V et al. Differentiation of type 1 T regulatory cells (Tr1) by tolerogenic DC-10 requires the IL-10-dependent ILT4/HLA-G pathway. Blood 2010; 116: 935– 44. 20448110
  169. [170]Franco, A, Kumar, J, Lin, G et al. Pediatric tolerogenic DCs expressing CD4 and immunoglobulin-like transcript receptor (ILT)-4 secrete IL-10 in response to Fc and adenosine. Eur J Immunol 2018; 48: 482– 91. 29244203
  170. [171]Stallone, G, Pontrelli, P, Infante, B et al. Rapamycin induces ILT3(high)ILT4(high) dendritic cells promoting a new immunoregulatory pathway. Kidney Int 2014; 85: 888– 97. 24107844
  171. [172]Warnecke-Eberz, U, Metzger, R, Holscher, AH et al. Diagnostic marker signature for esophageal cancer from transcriptome analysis. Tumour Biol 2016; 37: 6349– 58. 26631031
  172. [173]He, J, Xu, J, Yu, X et al. Overexpression of ANGPTL2 and LILRB2 as predictive and therapeutic biomarkers for metastasis and prognosis in colorectal cancer. Int J Clin Exp Pathol 2018; 11: 2281. 31938340 PMC6958241
  173. [174]Shao, H, Ma, L, Jin, F et al. Immune inhibitory receptor LILRB2 is critical for the endometrial cancer progression. Biochem Biophys Res Commun 2018; 506: 243– 50. 30343889
  174. [175]Carbone, C, Piro, G, Fassan, M et al. An angiopoietin-like protein 2 autocrine signaling promotes EMT during pancreatic ductal carcinogenesis. Oncotarget 2015; 6: 13822– 34. 25360865 PMC4537052
  175. [176]Colonna, M, Nakajima, H, Navarro, F et al. A novel family of Ig-like receptors for HLA class I molecules that modulate function of lymphoid and myeloid cells. J Leukoc Biol 1999; 66: 375– 81. 10496306
  176. [177]Tedla, N, Bandeira-Melo, C, Tassinari, P et al. Activation of human eosinophils through leukocyte immunoglobulin-like receptor 7. Proc Natl Acad Sci 2003; 100: 1174– 9. 12529506 PMC298746
  177. [178]Sloane, DE, Tedla, N, Awoniyi, M et al. Leukocyte immunoglobulin-like receptors: novel innate receptors for human basophil activation and inhibition. Blood 2004; 104: 2832– 9. 15242876
  178. [179]Hirayasu, K, Arase, H. Functional and genetic diversity of leukocyte immunoglobulin-like receptor and implication for disease associations. J Hum Genet 2015; 60: 703– 8. 26040207
  179. [180]Jones, DC, Hewitt, CR, Lopez-Alvarez, MR et al. Allele-specific recognition by LILRB3 and LILRA6 of a cytokeratin 8-associated ligand on necrotic glandular epithelial cells. Oncotarget 2016; 7: 15618– 31. 26769854 PMC4941265
  180. [181]Renauer, P, Saruhan-Direskeneli, G, Coit, P et al. Genome-wide association study identifies susceptibility loci in IL6, RPS9/LILRB3, and an intergenic locus on chromosome 21q22 in Takayasu’s arteritis. Arthritis Rheum 2015; 67: 1361. PMC4414813 25604533
  181. [182]Chen, S, Wen, X, Li, J et al. Association of FCGR2A/FCGR3A variant rs2099684 with Takayasu arteritis in the Han Chinese population. Oncotarget 2017; 8: 17239– 45. 27769046 PMC5370036
  182. [183]Renauer, P, Sawalha, AH. The genetics of Takayasu arteritis. Presse Med 2017; 46: e179– e87. 28756073 PMC5753771
  183. [184]Yoshifuji, H, Terao, C. Roles of cytotoxic lymphocytes and MIC/LILR families in pathophysiology of Takayasu arteritis. Inflamm Regen 2020; 40: 9. 32514324 PMC7265636
  184. [185]Ming, S, Li, M, Wu, M et al. Immunoglobulin-like transcript 5 inhibits macrophage-mediated bacterial killing and antigen presentation during sepsis. J Infect Dis 2019; 220: 1688– 99. 31250008
  185. [186]van der Touw, W, Kang, K, Luan, Y et al. Glatiramer acetate enhances myeloid-derived suppressor cell function via recognition of paired Ig-like receptor B. J Immunol 2018; 201: 1727– 34. 30068593 PMC6379207
  186. [187]Yeboah, M, Papagregoriou, C, Jones, DC et al. LILRB3 (ILT5) is a myeloid cell checkpoint that elicits profound immunomodulation. JCI Insight 2020; 5: e141593. PMC7526549 32870822
  187. [188]Chang, CC, Silvia, EA, Ho, EK et al. Polymorphism and linkage disequilibrium of immunoglobulin-like transcript 3 gene. Hum Immunol 2008; 69: 284– 90. 18486764
  188. [189]Arm, JP, Nwankwo, C, Austeen, KF. Molecular identification of a novel family of human Ig superfamily members that possess immunoreceptor tyrosine-based inhibition motifs and homology to the mouse gp49B1 inhibitory receptor. J Immunol 1997; 159: 2342– 9. 9278324
  189. [190]Vlad, G, Chang, CC, Colovai, AI et al. Immunoglobulin-like transcript 3: a crucial regulator of dendritic cell function. Hum Immunol 2009; 70: 340– 4. 19275918
  190. [191]Inui, M, Hirota, S, Hirano, K et al. Human CD43+ B cells are closely related not only to memory B cells phenotypically but also to plasmablasts developmentally in healthy individuals. Int Immunol 2015; 27: 345– 55. 25744616
  191. [192]Ulges, A, Klein, M, Reuter, S et al. Protein kinase CK2 enables regulatory T cells to suppress excessive TH2 responses in vivo. Nat Immunol 2015; 16: 267– 75. 25599562
  192. [193]Kim-Schulze, S, Seki, T, Vlad, G et al. Regulation of ILT3 gene expression by processing of precursor transcripts in human endothelial cells. Am J Transplant 2006; 6: 76– 82. 16433759
  193. [194]Cheng, H, Mohammed, F, Nam, G et al. Crystal structure of leukocyte Ig-like receptor LILRB4 (ILT3/LIR-5/CD85k): a myeloid inhibitory receptor involved in immune tolerance. J Biol Chem 2011; 286: 18013– 25. 21454581 PMC3093875
  194. [195]Xu, Z, Chang, CC, Li, M et al. ILT3.Fc-CD166 interaction induces inactivation of p70 S6 kinase and inhibits tumor cell growth. J Immunol 2018; 200: 1207– 19. 29263213
  195. [197]Verschueren, E, Husain, B, Yuen, K et al. The immunoglobulin superfamily receptome defines cancer-relevant networks associated with clinical outcome. Cell 2020; 182: 329– 44 e19. 32589946
  196. [198]Lu, HK, Rentero, C, Raftery, MJ et al. Leukocyte Ig-like receptor B4 (LILRB4) is a potent inhibitor of FcgammaRI-mediated monocyte activation via dephosphorylation of multiple kinases. J Biol Chem 2009; 284: 34839– 48. 19833736 PMC2787346
  197. [199]Park, M, Raftery, MJ, Thomas, PS et al. Leukocyte immunoglobulin-like receptor B4 regulates key signalling molecules involved in FcgammaRI-mediated clathrin-dependent endocytosis and phagocytosis. Sci Rep 2016; 6: 35085. 27725776 PMC5057125
  198. [200]Park, M, Liu, RW, An, H et al. A dual positive and negative regulation of monocyte activation by leukocyte Ig-like receptor B4 depends on the position of the tyrosine residues in its ITIMs. Innate Immun 2017; 23: 381– 91. 28409541
  199. [201]Jiang, Z, Qin, JJ, Zhang, Y et al. LILRB4 deficiency aggravates the development of atherosclerosis and plaque instability by increasing the macrophage inflammatory response via NF-kappaB signaling. Clin Sci (Lond) 2017; 131: 2275– 88. 28743735
  200. [202]Lv, W, Duan, Q, Wang, L et al. Expression of B-cell-associated genes in peripheral blood mononuclear cells of patients with symptomatic pulmonary embolism. Mol Med Rep 2015; 11: 2299– 305. 25411767

200 of 291 shown

Cited by

Sorted by citations

Authors
Deng, M., Chen, H., Liu, X., Huang, R., He, Y., Yoo, B., Xie, J., John, S., Zhang, N., An, Z., & Zhang, C. C.
Affiliations
  • The University of Texas Southwestern Medical Center (US)
  • Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases (US)
Corresponding author
Zhang, Cheng Cheng
ORCID
Venue
Antibody Therapeutics
Publisher
Oxford University Press (OUP)
Published
2021-01-01
Volume
4
Issue
1
Pages
16-33
ISSN
2516-4236 (ISSN-L)
DOI
10.1093/abt/tbab002
PMC
PMC7944505
OpenAlex
W3128104165
Cited by
53
References
5
Citations by year
2026: 5 · 2025: 16 · 2024: 10 · 2023: 12 · 2022: 8 · 2021: 2
FWCI
0.82
Type
journal article
Language
en
Open access
Licence
Locations
  • Antibody Therapeutics (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
  • National Cancer Institute (1R01 CA248736)
  • Cancer Prevention and Research Institute of Texas (RP180435, RP150551, RP190561)
  • Immune-Onc Therapeutics (#111077)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
leukocyte immunoglobulin-like receptors, ITIM, immune checkpoint, tumor immune evasion, cancer therapy targets, hematologic malignancies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review